Karuna Therapeutics Inc (KRTX) Stock
KRTX is no longer traded. Karuna Therapeutics was acquired by Bristol Myers Squibb (BMY) on March 18, 2024.
Each KRTX share was exchanged for $330.00 in cash. Prices on this page are historical; the last trade was March 8, 2024 at $319.95.
See Bristol Myers Squibb (BMY) stock →Karuna Therapeutics stock price history
KRTX final trading statistics
- Final close
- $319.95
- Final trading day
- Mar 8, 2024
- Market cap at delisting
- $12.22B
- Shares outstanding
- 38.20M
- Final 52-week range
- $158.38 – $321.45
- Avg. volume (final 3 mo.)
- 881,537
- All-time high (split-adj.)
- $320.85 · Feb 2024
- All-time low (split-adj.)
- $11.44 · Oct 2019
- Return since IPO
- +1498.2%
- Beta
- 1.15
- Book value / share
- $32.94
- Price / book
- 9.71
Karuna Therapeutics annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2023 | $654.0K | -$433.7M | -$11.72 |
| FY2022 | $10.64M | -$276.3M | -$8.72 |
| FY2021 | $36.96M | -$143.8M | -$4.90 |
| FY2020 | $0.00 | -$68.6M | -$2.58 |
| FY2019 | $0.00 | -$44.8M | -$2.46 |
Last five fiscal years reported before the delisting; fiscal year ending December. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.
About Karuna Therapeutics Inc
Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate includes KarXT, an oral modulator of muscarinic receptors for the treatment of acute psychosis in patients with schizophrenia; and for the treatment of central nervous system disorders, such as negative and cognitive symptoms of schizophrenia and psychosis, as well as for the treatment of various peripheral tissues and dementia-related psychosis, including Alzheimer's disease. The company also focuses on developing other muscarinic-targeted drug candidates; and intends to develop lead candidature TRPC4/5 and KAR-2618 for the treatment of depressive disorder. Karuna Therapeutics, Inc. has a license agreement with Eli Lilly and Company, and Zai Lab (Shanghai) Co., Ltd; patent license agreement with PureTech Health LLC; and drug discovery partnership with Charles River Laboratories, as well as drug discovery collaboration with PsychoGenics, Inc. The company was formerly known as Karuna Pharmaceuticals, Inc. and changed its name to Karuna Therapeutics, Inc. in March 2019. Karuna Therapeutics, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.
Karuna Therapeutics stock FAQ
What happened to Karuna Therapeutics stock?
Karuna Therapeutics was acquired by Bristol Myers Squibb (BMY) on March 18, 2024. Shareholders received $330.00 in cash for each share. KRTX stock stopped trading on the Nasdaq, with a final close of $319.95 on March 8, 2024.
What did Karuna Therapeutics shareholders receive?
Each KRTX share was converted into $330.00 in cash. The deal was valued at about $14 billion.
Is KRTX stock still trading?
No. KRTX was delisted from the Nasdaq on March 18, 2024 and no longer trades on a U.S. exchange.
What was the last price of KRTX stock?
KRTX closed at $319.95 on its final trading day, March 8, 2024, for a market value of about $12.22B.
What were Karuna Therapeutics's revenue and earnings in its last full fiscal year?
Karuna Therapeutics reported revenue of $654.0K and net income of -$433.7M in fiscal 2023, its last full year as a public company.
When did Karuna Therapeutics go public?
Karuna Therapeutics Inc stock began trading on June 28, 2019.